Oral Antibiotics Market Expected to Reach $23,306.10 million by 2027—Allied Market Research

According to a new report published by Allied Market Research, titled, “oral antibiotics market by class (beta lactam & beta lactamase inhibitors, quinolones, macrolide, and others), application (community-acquired respiratory tract infections (CARTIS), urinary tract infections (UTIS), dental, others), drug origin (natural, semisynthetic, synthetic), spectrum of activity (broad-spectrum antibiotic, mid/narrow-spectrum antibiotic), drug type (branded and generics): global opportunity analysis and industry forecast, 2019–2027,” the global oral antibiotics market was valued at $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, registering a CAGR of 2.7% from 2019 to 2027.

Antibiotics serve a useful therapeutic purpose for the treatment and control of pathogens. The medications are used to either inhibit or prevent bacterial infections referred as bactericidal and bacteriostatic antibiotics, respectively. Various types of antibiotics such as penicillin, cephalosporin, carbapenem, and monobactam are available in pharmacies and hospitals that are used to treat infectious diseases. However, the antibiotic resistance is a global problem and it is considered as a threat, owing to its effect on morbidity and mortality. The treatment with the help of oral antibiotics has the potential to reduce prolonged hospital stay, treatment cost, and further complications. Oral drug delivery continues to rise in popularity as key players are focused on extending R&D efforts, thereby improving patient convenience. 

The economies across the world are suffering from the impact of COVID-19 and many industries are experiencing losses. However, pharmaceutical companies have a center stage in the COVID-19 fight and are responding to rapid challenges. Whereas, the Covid-19 pandemic has impacted moderately on oral antibiotics market, as the coronavirus damages cells so badly that it becomes easier for certain bacteria to cause secondary infections. For instance, bacterial pneumonia in influenza patients, which can be treated with antibiotics. Hence, the macrolide antibiotics such as azithromycin, erythromycin, clarithromycin, and spiramycin are prescribing for the treatment of secondary infections.

The oral antibiotics market is expected to exhibit significant growth during the forecast period, owing to factors such as increased consumption in low and middle-income countries (LMICs) and rise in prevalence of infectious diseases along with imbalance of supply-demand of antibiotics. In addition, rise in R&D efforts undertaken by key players operating in the market for development of advanced oral antibiotics to treat bacterial infections and carry out a large number of clinical trials further supplements the market growth. In addition, use of novel approaches for development of new oral antibiotics for treating bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics, and the time taken for regulatory approvals are projected to hamper the market growth. Furthermore, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant opportunities for the market players. 

The current COVID-19 pandemic has highlighted the risk faced by older adults, who are more susceptible to complications such as acute respiratory distress syndrome, usually as a result of pneumonia. In the pandemic situation antibiotics are considered to have an important part in the disease treatment. COVID-19 has led to increase in the bacterial infections, as antibiotics are prescribed to prevent secondary infections following an antiviral immune response. Various antibiotics therapies have also been commonly used to support COVID19 treatments globally, which drives the use of oral antibiotics as the first line of treatment. 

Based on class, the beta lactam & beta lactamase inhibitors segment was the major revenue contributor in 2018, and is anticipated to continue this trend during the forecast period due to its spectrum of activity. These antibiotics are a class of broad-spectrum antibiotics. A broad-spectrum antibiotic acts against both Gram-positive & Gram-negative bacteria and effective on the infections with multiple groups of bacteria. Thus, the demand for beta lactam & beta lactamase inhibitors antibiotics is high. On the other side, the demand for quinolones is projected to exhibit the fastest market growth during the forecast period owing to the rise in demand of broad-spectrum bactericidal activity new generation quinolones, excellent oral bioavailability, good tissue penetration, and better safety & tolerability.

Depending on drug origin, the semisynthetic dominates the market in 2018, and is expected to remain dominant during the forecast period. This is attributed to the fact that the semisynthetic antibiotics have improved coverage and effectiveness against a wide range of organisms. Also, the semisynthetic antibiotics can be administered orally and its less costly to administer than other antibiotics in some cases.

Key Findings Of The Study

• By class, the beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018.

• On the basis of spectrum of activity, the broad-spectrum segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 3.3% from 2019 to 2027.

• Depending on application, the community-respiratory tract infections segment is expected to exhibit the highest CAGR during the forecast period.

• By drug origin, the semisynthetic segment was the major revenue contributor in 2018.

• By drug type, the branded segment accounted for largest revenue in 2018, and is expected to be dominant during the forecast period.

• LAMEA is estimated to grow at a CAGR of 3.3% during the forecast period.